Skip Navigation
 

Funding


RCDC

Project Listing by Category


Back to Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC) Click the column headings to sort project listings.
  Help
CategoryFYFunding ICProject NumberSub Project #Project TitlePI NameOrg NameState / CountryAmount
Uterine Cancer 2017 NCI 5R01CA183953-03 Cerenkov luminescence imaging for image-guided cancer surgery GRIMM, JAN SLOAN-KETTERING INST CAN RESEARCH NY $488,147
Uterine Cancer 2017 NCI 5R01CA193455-02 NCOA6, A Novel Tumor Suppressor of Endometrial Cancer XU, JIANMING BAYLOR COLLEGE OF MEDICINE TX $374,023
Uterine Cancer 2017 NCI 5R01CA172490-05 Characterizing and Targeting CHD4 Deficiency in Endometrial Cancer LIN, SHIAW-YIH UNIVERSITY OF TX MD ANDERSON CAN CTR TX $323,036
Uterine Cancer 2017 NCI 5UM1CA173642-05 Women's Health Initiative Cancer Survivor Cohort ANDERSON, GARNET FRED HUTCHINSON CANCER RESEARCH CENTER WA $2,260,718
Uterine Cancer 2017 NCI 5R01CA183877-03 Pathobiology and Mechanism of Progesterone Resistance in Human Endometrial Cancer MEMARZADEH, SANAZ UNIVERSITY OF CALIFORNIA LOS ANGELES CA $352,275
Uterine Cancer 2017 NCI 5R01CA175486-04 Systematic Functional Characterization of RNA Editing in Endometrial Cancer LIANG, HAN UNIVERSITY OF TX MD ANDERSON CAN CTR TX $332,000
Uterine Cancer 2017 NCCIH 5R01AT008824-02 Botanical derived progestins and their impact on women's health BURDETTE, JOANNA UNIVERSITY OF ILLINOIS AT CHICAGO IL $359,775
Uterine Cancer 2017 NCI 5R01CA196912-02 Novel tumorigenic mechanisms of the LKB1 tumor suppressor CASTRILLON, DIEGO UT SOUTHWESTERN MEDICAL CENTER TX $370,575
Uterine Cancer 2017 NCI 5R21CA205819-02 Modeling the impact of mutations in ubiquitin ligase genes on transcriptional programs in endometrial cancer LESLIE, CHRISTINA SLOAN-KETTERING INST CAN RESEARCH NY $186,398
Uterine Cancer 2017 NCI 5U10CA180868-04 NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER WOLMARK, NORMAN NRG ONCOLOGY FOUNDATION, INC. PA $13,475,638
Uterine Cancer 2017 NCI 5R01CA196975-02 First in-human PET imaging studies of NIS reporter [18F]BF4 DEGRADO, TIMOTHY MAYO CLINIC ROCHESTER MN $189,087
Uterine Cancer 2017 NCI 5R01CA099908-15 Targeted Therapy for Endometrial Cancer LESLIE, KIMBERLY UNIVERSITY OF IOWA IA $252,448
Uterine Cancer 2017 NCI 5R01CA200864-02 Molecular Classification of High Grade Endometrial Cancers: Extending TCGA Findings to a Diverse Population COTE, MICHELE WAYNE STATE UNIVERSITY MI $618,743
Uterine Cancer 2017 NCI 5U01CA176067-04 Integrated genomic analysis of racial disparities in endometrial cancer SANTIN, ALESSANDRO YALE UNIVERSITY CT $348,353
Uterine Cancer 2017 NCI 5R01CA168755-05 Inflammation and immunity in the crucible of premalignancy ERLEBACHER, ADRIAN UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CA $455,336
Uterine Cancer 2017 NCI 5R01CA175100-05 Revving-Up Exercise for Sustained Weight-Loss by Altering Neurological Reward & D NOCK, NORA CASE WESTERN RESERVE UNIVERSITY OH $432,930
Uterine Cancer 2017 NCI 5R01CA176502-04 Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer GOLD, LESLIE NEW YORK UNIVERSITY SCHOOL OF MEDICINE NY $579,879
Uterine Cancer 2017 NCI 5R00CA184043-05 Targeting Ovarian Cancer via Cooperative Oncogene Interactions HARGREAVES, DIANA SALK INSTITUTE FOR BIOLOGICAL STUDIES CA $249,000
Uterine Cancer 2017 NICHD 5R01HD042311-14 Molecular Analysis of Uterine Receptivity LYDON, JOHN BAYLOR COLLEGE OF MEDICINE TX $328,888
Uterine Cancer 2017 NCI 1R01CA216103-01 Molecular Mechanisms Underlying Environmental Effects that Influence Penetrance in Lynch Syndrome-Associated Endometrial Cancer YATES, MELINDA UNIVERSITY OF TX MD ANDERSON CAN CTR TX $256,000
Uterine Cancer 2017 NCI 1R01CA207240-01A1 Phase I trial of intravenous vesicular stomatitis virus for treatment of metastatic endometrial cancer BAKKUM-GAMEZ, JAMIE MAYO CLINIC ROCHESTER MN $472,577
Uterine Cancer 2017 NCI 1R01CA211339-01A1 Next-Generation Mouse Models of Endometrial Cancer CASTRILLON, DIEGO UT SOUTHWESTERN MEDICAL CENTER TX $570,932
Uterine Cancer 2017 NCI 5P30CA091842-16 6318 Solid Tumor Therapeutics (Project-007) EBERLEIN, TIMOTHY WASHINGTON UNIVERSITY MO $60,053
Uterine Cancer 2017 NICHD 5R21HD086402-02 Mechanisms of PGRMC1 Action in Endometrial Proliferation PRU, JAMES WASHINGTON STATE UNIVERSITY WA $229,500
Uterine Cancer 2017 NCI 5R01CA172279-04 Novel epigenetic paradigm in endometrial cancer recurrence HUANG, TIM UNIVERSITY OF TEXAS HLTH SCIENCE CENTER TX $308,364
Uterine Cancer 2017 NCI 5R01CA184101-04 MTDH regulates Fanconi anemia repair pathway to mediate drug resistance MENG, XIANGBING UNIVERSITY OF IOWA IA $313,622
Uterine Cancer 2017 NCI 5R01CA192438-04 Epidemiology of the four most frequent cancers following breast cancer MALONE, KATHLEEN FRED HUTCHINSON CANCER RESEARCH CENTER WA $956,771
Uterine Cancer 2017 NCI 5P50CA098258-12 8325 Administrative Core LU, KAREN UNIVERSITY OF TX MD ANDERSON CAN CTR TX $283,265
Uterine Cancer 2017 NCI 5P50CA098258-12 8326 Pathology Core BROADDUS, RUSSELL UNIVERSITY OF TX MD ANDERSON CAN CTR TX $200,000
Uterine Cancer 2017 NCI 5P50CA098258-12 8327 Biomarkers Core LOOSE, DAVID UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON TX $48,774
Uterine Cancer 2017 NCI 5P50CA098258-12 8328 Biostatistics and Bioinformatics Core YUAN, YING UNIVERSITY OF TX MD ANDERSON CAN CTR TX $199,998
Uterine Cancer 2017 NCI 5P50CA098258-12 8329 Developmental Research Program BURKE, THOMAS UNIVERSITY OF TX MD ANDERSON CAN CTR TX $159,998
Uterine Cancer 2017 NCI 5P50CA098258-12 8330 Career Enhancement Program BODURKA, DIANE UNIVERSITY OF TX MD ANDERSON CAN CTR TX $159,997
Uterine Cancer 2017 NCI 5P50CA098258-12 8331 P1: Novel Targeted Strategies for Prevention and Conservative Management of Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Cancer LU, KAREN UNIVERSITY OF TX MD ANDERSON CAN CTR TX $311,994
Uterine Cancer 2017 NCI 5P50CA098258-12 8332 P2: CTNNB1 Mutation and Wnt Pathway Activation Define Clinically Aggressive Endometrioid Endometrial Carcinoma BROADDUS, RUSSELL UNIVERSITY OF TX MD ANDERSON CAN CTR TX $311,991
Uterine Cancer 2017 NCI 5P50CA098258-12 8333 P3: EphA2 Targeting in Uterine Carcinoma SOOD, ANIL UNIVERSITY OF TX MD ANDERSON CAN CTR TX $311,990
Uterine Cancer 2017 NCI 5P50CA098258-12 8334 P4: A Framework for Identification of Novel Targeted Therapy Combinations in Endometrial Cancer MILLS, GORDON UNIVERSITY OF TX MD ANDERSON CAN CTR TX $311,990
Uterine Cancer 2017 NCI 5U54CA143931-08 5570 PARP inhibition with hormonal modulation as a therapy for PTEN driven endometrial tumors MEMARZADEH, SANAZ CHARLES R. DREW UNIVERSITY OF MED & SCI CA $53,813
Uterine Cancer 2017 NIGMS 5R01GM112524-05 Regulation of the Class IA PI 3-kinase PIK3CB BACKER, JONATHAN ALBERT EINSTEIN COLLEGE OF MEDICINE, INC NY $404,897
Uterine Cancer 2017 NCI 5R44CA203350-03 Genetic Cytology for Ovarian and Endometrial Cancer Screening KINDE, ISAAC PAPGENE, INC. MD $994,554
Uterine Cancer 2017 NCI 5U54CA143930-08 6423 PARP inhibition with hormonal modulation as a therapy for PTEN driven endometrial tumors MEMARZADEH, SANAZ UNIVERSITY OF CALIFORNIA LOS ANGELES CA $60,125
Uterine Cancer 2017 NIGMS 5R01CA194496-02 Molecular Mechanisms and Applications of Novel ER/GPER-selective Ligands PROSSNITZ, ERIC UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR NM $320,000
Uterine Cancer 2017 NCI 5F99CA212222-02 Inflammation and gynecologic cancer: the role of prostaglandins in ovarian cancer BARNARD, MOLLIE HARVARD SCHOOL OF PUBLIC HEALTH MA $31,260
Uterine Cancer 2017 NICHD 5R21HD087589-02 Generation of a Model to Study Uterine Gland Function SPENCER, THOMAS UNIVERSITY OF MISSOURI-COLUMBIA MO $191,875
Uterine Cancer 2017 NCI 1R01CA218287-01 Signature-guided therapy for mismatch repair defective cancers LIN, SHIAW-YIH UNIVERSITY OF TX MD ANDERSON CAN CTR TX $373,331
Uterine Cancer 2017 NCI 1R03CA212808-01A1 A pooled analysis of dietary long-chain omega-3 fatty acid intake and endometrial cancer risk BRASKY, THEODORE OHIO STATE UNIVERSITY OH $77,542
Uterine Cancer 2017 NCI 3P50CA098258-12S1 7324 Molecular Modifiers of Endometrial Endometrioid Adenocarcinoma Immune Microenvironment: Impact of PTEN loss and CD73-Generated Adenosine Loss BROADDUS, RUSSELL UNIVERSITY OF TX MD ANDERSON CAN CTR TX $192,000
Uterine Cancer 2017 NCI 3UM1CA173642-05S1 Women's Health Initiative Cancer Survivor Cohort ANDERSON, GARNET FRED HUTCHINSON CANCER RESEARCH CENTER WA $56,922
Uterine Cancer 2017 NCI 3UM1CA173642-05S2 Women's Health Initiative Cancer Survivor Cohort ANDERSON, GARNET FRED HUTCHINSON CANCER RESEARCH CENTER WA $165,708
Uterine Cancer 2017 NCI 3R01CA176502-04S1 Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer GOLD, LESLIE NEW YORK UNIVERSITY SCHOOL OF MEDICINE NY $60,511
Uterine Cancer 2017 NCI 3U10CA180868-04S1 NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER WOLMARK, NORMAN NRG ONCOLOGY FOUNDATION, INC. PA $133,213
Uterine Cancer 2017 NCI 1R21CA220269-01 Inter-relationship between microbiota diversity, obesity and race in endometrial cancer BAE-JUMP, VICTORIA UNIV OF NORTH CAROLINA CHAPEL HILL NC $202,928
Uterine Cancer 2017 NCI 1F32CA221007-01 The role of mRNA methylation in the progression of endometrial cancer HARADA, BRYAN UNIVERSITY OF CHICAGO IL $56,694
Uterine Cancer 2017 NCI 1R44CA221398-01 Clinical Efficacy Evaluation of First-in-class Imipridone ONC201 in Recurrent Type II Endometrial Cancer OSTER, WOLFGANG ONCOCEUTICS, INC. PA $224,000
Uterine Cancer 2017 NCI 261200800001E-111-0-35 Genotyping for epidemiology studies HEIMBROOK, DAVID LEIDOS BIOMEDICAL RESEARCH, INC. MD $2,623,215
Uterine Cancer 2017 NCI 261200800001E-111-0-36 Repository Services for epidemiology studies HEIMBROOK, DAVID LEIDOS BIOMEDICAL RESEARCH, INC. MD $1,380,084
Uterine Cancer 2017 NCI 1ZIACP010126-22 Hormone-Related Cancers GIERACH, GRETCHEN NIH $3,383,977
Uterine Cancer 2017 NCI 1ZIACP010128-22 Therapeutic and Diagnostic Factors as Related to Cancer Risk TRABERT, BRITTON NIH $516,496
Uterine Cancer 2017 NCI 1ZIACP010182-15 Epidemiologic Field Studies SCHAIRER, CATHERINE NIH $767,797
Uterine Cancer 2017 NCI 1ZIACP010187-13 Cancer Genetic Markers of Susceptibility HOOVER, ROBERT NIH $106,767
Uterine Cancer 2017 NCI 1ZIABC005177-37 Interaction of Chemical Carcinogens and Chemotherapeutic Agents with DNA POIRIER, MIRIAM NIH $59,366
Uterine Cancer 2017 NCI 261201500038I-0-26100008-1 IGF::OT::IGF PREVENTION OF ENDOMETRIAL HYPERPLASIA AND ITS TRANSITION TO ENDOMETRIAL CANCER WITH SHETA2 POP 6/1/2017 - 5/31/2019 RAO, C V UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR OK $713,988
Uterine Cancer 2017 NHGRI 1ZIAHG200330-13 Comparative Genomics Analysis Unit Research MULLIKIN, JAMES NIH $1,224,515
Uterine Cancer 2017 NHGRI 1ZIAHG200379-06 Identification of genetic alterations that underlie endometrial carcinosarcomas BELL, DAPHNE NIH $302,887
Uterine Cancer 2017 NHGRI 1ZIAHG200323-13 Genomic, Epigenetic and Functional Analyses of Vertebrate Regulatory Regions ELNITSKI, LAURA NIH $1,748,348
Uterine Cancer 2017 NHGRI 1ZIAHG200338-11 Genomic Analyses of Endometrial Cancer BELL, DAPHNE NIH $1,114,546
Uterine Cancer 2017 NCI 261201600012I-0-26100002-1 TSS CPTAC Digital Medical Images of CPTAC Biospecimens GASPARIAN, ALEXANDER NIH CA $66,300
Uterine Cancer 2017 NCI 261201200033I-0-26100011-1 IGF::OT::IGF PILOT STUDY OF DAILY EXEMESTANE IN WOMEN WITH COMPLEX ATYPICAL HYPERPLASIA OF THE ENDOMETRIUM/ENDOMETRIAL INTRAEPITHELIAL NEOPLASIA OR GRADE 1 ENDOMETRIAL CANCER BAILEY, HOWARD UNIVERSITY OF WISCONSIN-MADISON WI $277,191


  • Download Readers:
  • Download Adobe PDF Reader
  • Download Microsoft PowerPoint Viewer
  • Download Microsoft Word Viewer
  • Download Microsoft Excel Viewer